Illumina Ventures: Timothy Stenzel, Jerry Steiner
Timothy Stenzel and Jerry Steiner have joined Illumina Ventures as advisers.
Stenzel is the former director of the US Food and Drug Administration's Office of In Vitro Diagnostics. He has also been chief operating officer of Invivoscribe, CSO of Quidel, and a faculty member at Duke University School of Medicine. He holds an M.D. and a Ph.D. in microbiology and immunology from Duke.
Steiner is executive chairman of Pluton Biosciences, an Illumina Ventures portfolio company. Previously, he was executive VP of sustainability and global corporate affairs at Monsanto, and before that, Monsanto's VP of product and corporate strategy and general manager in the US and Europe. Earlier, he was part of the leadership team at Celera Genomics. He holds an MBA from Washington University in St. Louis and a B.S. in agricultural economics from the University of Wisconsin.
Guardant Health: Manuel Hidalgo Medina
Guardant Health has appointed Manuel Hidalgo Medina to its board of directors, effective immediately. Hidalgo currently serves as chief of hematology and medical oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. His career includes prior roles as chief of the division of hematology at Beth Israel Deaconess Medical Center in Boston, clinical director of the Rosenberg Clinical Cancer Center, and leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and the Kimmel Comprehensive Cancer Center. He is also a member of the board at Bristol Myers Squibb.
Global Genomic Medicine Collaborative: Grant Wood
The Global Genomic Medicine Collaborative (GGMC), a nonprofit organization dedicated to translating genomic research into clinical practice, improving patient care, and reducing health disparities, has appointed Grant Wood as its new CEO, replacing outgoing CEO Tejinder Rakhra-Burris.
Wood has been an active member of GGMC since 2014 and is involved in several other prominent organizations in the technology and genomics space, including Health Level 7 International (HL7), the Global Alliance for Genomics and Health (GA4GH), AlphaNet, and the US Centers for Disease Control and Prevention's National Family Health History Group. He previously served as senior information technology strategist at Intermountain Healthcare Clinical Genetics.
Seer: Rachel Haurwitz
Seer said that Rachel Haurwitz has resigned from her position as a member of the company's board of directors effective July 8. Seer appointed Haurwitz to its board in 2021. She is the cofounder, CEO, and president of Caribou Biosciences.
Genetic Technologies: Mark Ziirsen
Genetic Technologies has appointed Mark Ziirsen as its CFO and company secretary. He has more than 25 years of experience in the life sciences, technology, and consumer segments, including leadership roles in finance with companies listed on the Australian Stock Exchange, such as Cochlear, Aristocrat Leisure, Coca-Cola Amatil, and Goodman Fielder. Ziirsen also founded CFO advisory firm Mark Ziirsen Advisory, according to his LinkedIn profile.
For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.